Stat6 aso
WebSTAT6 −/− mice have increased lethality, inflammation, and cytokine production in a noninfection induced model of endotoxemia, but reduced lethality and enhanced clearance of bacteria in an infection model. STAT6 induces expression of GATA3, which is considered the Th2 cell master regulator. WebJun 30, 2024 · In HCC models, exoASO-STAT6 induced significant knockdown of STAT6 mRNA, attenuated tumor growth and induced complete remission of tumor lesions in 50% …
Stat6 aso
Did you know?
WebJul 1, 2024 · Conclusion: exoASO-STAT6 is a novel therapeutic that selectively targets STAT6, a key transcription factor in TAMs. This therapy results in effective macrophage reprogramming to a pro-inflammatory M1 phenotype and potent single agent anti-tumor activity in multiple checkpoint refractory tumor models. WebNov 17, 2024 · ExoASO STAT6 is an engineered exosomes, surface loaded with an antisense oligonucleotide (ASO) targeting immune suppressive macrophages (M2) and monocytes, exoASO STAT6 ... exoASO STAT6 Alternative Names: CDK 004; exoASO™-STAT6 Latest Information Update: 17 Nov 2024. Price : $50 * Buy Profile. Adis is an …
WebNov 10, 2024 · Codiak’s exoASO-STAT6 is an engineered exosome investigational therapeutic candidate designed to selectively deliver antisense oligonucleotides (ASOs) to … WebBackground exoASO-STAT6™ is an investigational therapeutic candidate consisting of exosomes loaded with an antisense oligonucleotide (ASO) targeting STAT6. By leveraging exosome tropism to tumor-associated macrophages (TAM), exoASO-STAT6™ is the first systemically administered exosome designed to selectively silence STAT6 in TAMs, …
WebMar 1, 2024 · Phospho-STAT6 is a major downstream signal transducer for IL-4/IL-13-dependent genes (Lin et al., 1995). In hepatic macrophages lacking IL-4Rα, there was … WebFeb 18, 2024 · exoASO-STAT6 is an engineered exosome therapeutic candidate which selectively delivers antisense oligonucleotides to down-modulate STAT6 mRNA …
WebFeb 18, 2024 · Based on our preclinical observations, we believe exoASO-STAT6 is the first macrophage targeting candidate to show single agent anti-tumor activity of this magnitude, thus offering the potential...
WebApr 10, 2024 · Both exoASO-STAT6 and exoIL-12 were developed via Codiak’s proprietary engEx™ Platform, which enables the company to engineer exosomes – naturally occurring, extracellular vesicles – with... my elder scrolls online accountWebFeb 18, 2024 · This novel engineered exosome, exoASO-STAT6, demonstrates maximal biodistribution and STAT6-silencing activity in the liver after intravenous administration, with minimal effects in other tissues. exoASO-STAT6 shows robust antitumor activity as a monotherapy in multiple preclinical tumor models by inducing remodeling of the TME. my elearning ahaWebApr 3, 2024 · Administration of the engineered exosome delivering an antisense oligonucleotide (ASO) targeting STAT6 (exoASO-STAT6), which could selectively silence STAT6 expression in TAMs, induces ... my elearnhereWebFeb 18, 2024 · We describe an engineered exosome therapeutic candidate delivering an antisense oligonucleotide (ASO) targeting STAT6 (exoASO-STAT6), which selectively … my e learning account nhsWebConclusions In summary, we demonstrated that exoASO-STAT6 has a durable PK/PD profile in the liver of preclinical species, identified PD biomarkers with good clinical translational … official assignee nzWebSTAT6 is also involved in IL4 signaling in B cells, and STAT6 determines the levels of CD20 on the surface of normal and malignant B lymphocytes. STAT6 also plays a critical role in Th2 lung inflammatory responses including clearance of parasitic infections and in the pathogenesis of asthma. my e learning anchor hanoverWebWe found that STAT6 ASO plus hRT slowed growth of both primary and abscopal tumors, decreased lung metastases, and extended survival. Interrogating the mechanism of action … official assignee office